MagForce AG (MGFRF)
- EQS Group
MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
DGAP-News: MagForce AG / Key word(s): Study08.04.2022 / 09:00 The issuer is solely responsible for the content of this announcement.MagForce AG: MagForce USA, Inc. receives Payment Code Approval by the American Medical Association for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System Category III CPT codes will ensure seamless billing and tracking process for payers already at the time FDA marketing approval is secured NanoTherm Therapy CPT codes will support MagForce's req
- EQS Group
MagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million
MagForce AG / Key word(s): Corporate ActionMagForce AG extends EUR 5.0 million Convertible Notes agreement with Lansdowne Investment Company Cyprus Limited and issues additional Convertible Notes in the amount of EUR 2.0 million25-Feb-2022 / 22:19 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Disclosure of an insider inform
- EQS Group
Original-Research: MagForce AG (von GBC AG)
Original-Research: MagForce AG - von GBC AG Einstufung von GBC AG zu MagForce AG Unternehmen: MagForce AG ISIN: DE000A0HGQF5 Anlass der Studie: GBC Management Interview Empfehlung: GBC Management Interview Letzte Ratingänderung: Analyst: Cosmin Filker In the past fiscal year 2021, MagForce AG made progress in both business segments. Of particular note here is the approval granted by the FDA for the start of Stage 2b for the treatment of prostate cancer patients. This means that the pivotal study
